Importantly, recent work has shown that dasatinib (or other TKI) delivery to brain tumor parenchyma may be further improved by strategies to inhibit active efflux proteins (P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1)). This evidence concerns the gene ABCB1 and brain neoplasm.